SCHEMBL2194477

SCHEMBL2194477

COCc1nnc(NS(=O)(=O)c2ccc(N)cc2)s1

nearest known ligand 0.79

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RECQL P46063 1/20 0.79
SMN1; SMN2 Q16637 1/20 0.77
ALDH1A1 P00352 9/20 0.76
AKT1 P31749 2/20 0.74
HPGD P15428 2/20 0.72
LMNA P02545 1/20 0.63
CA12 O43570 1/20 0.58
CA1 P00915 1/20 0.58
CA2 P00918 1/20 0.58
CA3 P07451 1/20 0.58
CA6 P23280 1/20 0.58
CA5A P35218 1/20 0.58
CA9 Q16790 1/20 0.58
CA14 Q9ULX7 1/20 0.58
CA5B Q9Y2D0 1/20 0.58
PKM P14618 2/20 0.57
HSD17B10 Q99714 2/20 0.55
ATM Q13315 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30209709 0.87 RECQL (0.79) RECQLSMN1; SMN2ALDH1A1AKT1HPGD
SCHEMBL5394947 0.87 SMN1; SMN2 (1.00) RECQLSMN1; SMN2ALDH1A1AKT1HPGD
Sulfaethidole SCHEMBL152872 0.85 AKT1 (1.00) ALDH1A1AKT1HPGDLMNACA12
SCHEMBL11893089 0.85 AKT1 (0.79) RECQLSMN1; SMN2ALDH1A1AKT1HPGD
SCHEMBL11891692 0.85 AKT1 (0.70) RECQLSMN1; SMN2ALDH1A1AKT1HPGD
Sulfaethidole SCHEMBL10510090 0.84 AKT1 (0.97) ALDH1A1AKT1HPGDLMNACA12
SCHEMBL11891693 0.84 AKT1 (0.69) RECQLSMN1; SMN2ALDH1A1AKT1LMNA
SCHEMBL2196666 0.84 ALDH1A1 (1.00) RECQLSMN1; SMN2ALDH1A1AKT1HPGD
Sulfaethidole SCHEMBL1651230 0.83 AKT1 (0.95) ALDH1A1AKT1HPGDLMNACA12
SCHEMBL283033 0.82 AKT1 (0.75) RECQLALDH1A1AKT1HPGDLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130022629-A1 Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2013-01-24 US disclosed
US-20130022629-A1 Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2013-01-24 US disclosed
WO-2011082400-A2 MODULATORS OF IMMUNOINHIBITORY RECEPTOR PD-1, AND METHODS OF USE THEREOF PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2011-07-07 WO disclosed
WO-2011082400-A2 MODULATORS OF IMMUNOINHIBITORY RECEPTOR PD-1, AND METHODS OF USE THEREOF PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2011-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130022629-A1 Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof CD274, PDCD1LG2, PDCD1 RECQL 2937/4885SMN1; SMN2 4661/4885ALDH1A1 380/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.